Recurrent Anaplastic Astrocytoma
6
1
3
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 90/100
33.3%
2 terminated out of 6 trials
0.0%
-86.5% vs benchmark
17%
1 trials in Phase 3/4
0%
2 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (6)
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
Fimepinostat in Treating Brain Tumors in Children and Young Adults
Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas
Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients